Lemborexant
- Generic Name
- Lemborexant
- Brand Names
- Dayvigo
- Drug Type
- Small Molecule
- Chemical Formula
- C22H20F2N4O2
- CAS Number
- 1369764-02-2
- Unique Ingredient Identifier
- 0K5743G68X
- Background
Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to "switch-off" wake-promoting circuits. Whereas historically popular pharmacologic treatments for insomnia (e.g. zopiclone, zolpidem, benzodiazepines) focus on enhancing sleep drive via modulation of GABA and melatonin receptors, lemborexant and other orexin antagonists (e.g. suvorexant) act to counteract inappropriate wakefulness. This novel mechanism of action offers potential advantages over classic hypnotic agents, including a more favorable adverse effect profile and potentially greater efficacy, and may signal the beginning of a new wave of treatment options for patients suffering from insomnia.
- Indication
Lemborexant is indicated for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
- Associated Conditions
- Insomnia
Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects
- Conditions
- Opioid Use DisorderOpioid UseInsomniaOrexin Antagonist
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 100
- Registration Number
- NCT06981195
- Locations
- 🇺🇸
VCU Institute for Drug and Alcohol Studies, Richmond, Virginia, United States
Effects of Eszopiclone and Lemborexant in People With OSA With a Low Arousal Threshold Who Have Difficulty Sleeping
- Conditions
- OSA - Obstructive Sleep Apnea
- Interventions
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Flinders University
- Target Recruit Count
- 15
- Registration Number
- NCT06928766
- Locations
- 🇦🇺
Flinders University, Adelaide Institute for Sleep Health, Bedford Park, South Australia, Australia
A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults with Insomnia.
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Woolcock Institute of Medical Research
- Target Recruit Count
- 20
- Registration Number
- NCT06823752
- Locations
- 🇦🇺
Woolcock Institute of Medical Research, Macquarie Park, New South Wales, Australia
Lemborexant in Delayed Sleep Phase Syndrome
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 15
- Registration Number
- NCT06874855
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD)
- Conditions
- Major Depressive Disorder(MDD)Insomnia Comorbid to Psychiatric Disorder
- Interventions
- Other: Placebo
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Unity Health Toronto
- Target Recruit Count
- 30
- Registration Number
- NCT06843187
- Locations
- 🇨🇦
St. Michael's Hospital, Unity Health Toronto, Toronto, Ontario, Canada
Efficacy of CBT-I and Lemborexant Medication for Different Subtypes of Chronic Insomnia
- Conditions
- Insomnia Disorder
- Interventions
- First Posted Date
- 2025-01-16
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Laval University
- Target Recruit Count
- 90
- Registration Number
- NCT06779149
- Locations
- 🇨🇦
Université Laval Centre d'étude des troubles du sommeil, Québec, Quebec, Canada
Lemborexant to Prevent Post-operative Delirium in Cardiac Surgery Patients
- Conditions
- Delirium - PostoperativeCardiac SurgeryCardiac Surgery SubjectsOrexin AntagonistFeasibility StudiesSleepIn-hospital Mortality
- Interventions
- Drug: Control (placebo) group
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 60
- Registration Number
- NCT06648681
- Locations
- 🇨🇦
St. Paul's Hospital, Vancouver, British Columbia, Canada
Lemborexant on Improving Sleep Quality Among Hospital Rotating Shift Workers
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Phramongkutklao College of Medicine and Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06496282
- Locations
- 🇹🇭
Phramongkutklao Hospital, Ratchathewi, Bangkok, Thailand
DORA and LP in Alzheimer's Disease Biomarkers
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 201
- Registration Number
- NCT06274528
- Locations
- 🇺🇸
Washington University in St. Louis, School of Medicine, Saint Louis, Missouri, United States
Lemborexant Treatment of Insomnia Linked to Epilepsy
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- University of Manitoba
- Target Recruit Count
- 26
- Registration Number
- NCT06262594
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇨🇦Health Sciences Centre, Winnipeg, Manitoba, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.